According to available clinical data,≈ 15% to 30% of the COVID-19 patients are with
hypertension and≈ 2.5% to 15% are with coronary heart disease. 3–5 …

Abstract Purpose of Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic …

Renin–angiotensin system (RAS) blockers are extensively used worldwide to treat many
cardiovascular disorders, where they are effective in reducing both mortality and morbidity …

The effects of ACE inhibitors (ACEis) and angiotensin receptor blockers (ARBs) on ACE2
expression and activity are unclear. Concerns arose about possible interactions between …

China, in December 2019. 1 As of March 20, 2020, 244 602 patients have tested positive
worldwide; and 10 031 (4.1%) of these patients were reported to be deceased because of …

Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2
protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has already surpassed the combined mortality …

Severe acute respiratory-syndrome coronavirus-2 (SARS-CoV-2) host cell infection is
mediated by binding to angiotensin-converting enzyme 2 (ACE2). Systemic dysregulation …

We thank Mourad and Levy for their constructive Correspondence (Interaction between
RAAS inhibitors and ACE2 in the context of COVID-19. Nat. Rev. Cardiol. https://doi …

Mortality from coronavirus disease 2019 (COVID-19) is strongly associated with
cardiovascular disease, diabetes, and hypertension. These disorders share underlying …